Payment overview · 2025
General Payments
$624.14
26 reported records · 14 companies
Healthcare provider profile · identity verified
Austin W Sorchik, DO
Allopathic & Osteopathic Physicians|Family Medicine · VALDOSTA, GA · NPI 1598256331
Verified facts
What the public records show
CMS Open Payments records show Austin W Sorchik, DO received $624.14 in general payments during 2025 across 26 reported records.
Abbott Laboratories accounted for 13.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $80.99 | 13.0% | 4 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $70.10 | 11.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $69.59 | 11.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $67.04 | 10.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $56.29 | 9.0% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $53.41 | 8.6% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $52.05 | 8.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.48 | 5.4% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $32.33 | 5.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.98 | 4.5% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.08 | 3.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.07 | 3.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.03 | 2.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.70 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $624.14 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $85.07 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $80.99 | 4 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $70.10 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $69.59 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $53.41 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $52.05 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.17 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.17 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $32.33 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $32.33 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $27.98 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.51 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 110 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 22 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 306 | 79 |
| Metformin Hcl | Metformin Hcl | 238 | 63 |
| Gabapentin | Gabapentin | 225 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 213 | 61 |
| Lisinopril | Lisinopril | 200 | 47 |
| Losartan Potassium | Losartan Potassium | 191 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 47 |
| Montelukast Sodium | Montelukast Sodium | 151 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 150 | 30 |
| Potassium Chloride | Potassium Chloride | 125 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 122 | 28 |
| Omeprazole | Omeprazole | 120 | 28 |
| Furosemide | Furosemide | 119 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 33 |
| Ozempic | Semaglutide | 110 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 32 |
| Trazodone Hcl | Trazodone Hcl | 91 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 18 |
| Carvedilol | Carvedilol | 81 | 18 |
| Famotidine | Famotidine | 79 | 20 |
| Jardiance | Empagliflozin | 77 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 18 |
| Mounjaro | Tirzepatide | 64 | suppressed |
| Simvastatin | Simvastatin | 64 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 13 |
| Farxiga | Dapagliflozin Propanediol | 59 | 12 |
| Methylprednisolone | Methylprednisolone | 59 | 51 |
| Donepezil Hcl | Donepezil Hcl | 58 | 11 |
| Trulicity | Dulaglutide | 57 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 16 |
| Celecoxib | Celecoxib | 55 | 12 |
| Fluconazole | Fluconazole | 54 | 36 |
| Spironolactone | Spironolactone | 53 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 52 | 11 |
| Ezetimibe | Ezetimibe | 50 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 11 |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 12 |
| Alendronate Sodium | Alendronate Sodium | 41 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 19 |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 30 |
| Glipizide | Glipizide | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Valsartan | Valsartan | 30 | 12 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | 15 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Nifedipine Er | Nifedipine | 27 | 11 |
| Valacyclovir | Valacyclovir Hcl | 27 | suppressed |
| Eliquis | Apixaban | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Prednisone | Prednisone | 23 | 16 |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 11 |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 11 |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $624.14 · 26 records | Abbott Laboratories | ABRYSVO, ACCRUFER, Auvelity, FREESTYLE LIBRE, Fluad, Flucelvax, Leqembi, NURTEC ODT, NUZYRA, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, TZIELD, UBRELVY, Veozah, WATCHMAN Access System, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error